Jeeva Clinical Trials Unveils Partnership Program to Accelerate Next-Gen Clinical Trials with Unified, AI-Driven CTMS

March 18, 2025 04:14 PM AEDT | By EIN Presswire
 Jeeva Clinical Trials Unveils Partnership Program to Accelerate Next-Gen Clinical Trials with Unified, AI-Driven CTMS
Image source: EIN Presswire
MANASSAS, VA, UNITED STATES, March 18, 2025 /EINPresswire.com/ -- Jeeva Clinical Trials (“Jeeva”), a leader in decentralized and hybrid clinical trial technology, today announced the launch of its Contract Research Organizations (CRO) Partnership Program, inviting forward-thinking CROs to join the era of real-time collaboration, AI-driven trial management, and seamless site-sponsor connectivity through its unified Clinical Trial Management System (CTMS).

This strategic initiative is designed to empower niche CROs specializing in obesity, dermatology, oncology, and rare diseases by equipping them with best-in-class digital solutions to enhance study speed, compliance, patient retention, and cost efficiency.
“CROs are the backbone of clinical trials, yet the industry still struggles with fragmented workflows, manual processes, and delayed decision-making,” said Harsha K Rajasimha, PhD, CEO and Founder of Jeeva. “It’s time to bridge the gap between sponsors, CROs, sites, and technology providers by enabling real-time collaboration on a unified, AI-powered platform. Our partnership program invites innovative CROs to modernize trials, accelerate approvals, and improve patient outcomes with a fully integrated CTMS solution.”

The Critical Need for Real-Time Collaboration in Clinical Research
The traditional siloed approach to clinical trials—where sponsors, CROs, and sites operate on disjointed systems with slow, manual data sharing—is no longer sustainable. The challenges of poor site coordination, recruitment delays, compliance risks, and operational inefficiencies have long plagued the industry, leading to:
✅ 60% of clinical trials experiencing costly delays
✅ $1.5 million lost per day due to trial inefficiencies
✅ High dropout rates due to poor patient engagement and site burden
✅ Regulatory bottlenecks from fragmented data collection and compliance gaps
Jeeva’s unified CTMS platform eliminates these inefficiencies by providing a centralized, AI-driven ecosystem that connects sponsors, CROs, sites, and patients in real-time. The launch of the CRO Partnership Program ensures that innovative, forward-thinking CROs can harness the power of automation, AI, and remote trial capabilities to optimize every phase of study execution.
“We are thrilled to partner with Jeeva to bring next-generation efficiencies to clinical research. The need for AI-driven automation in clinical trials has never been greater, and a unified CTMS approach is exactly what the industry needs,” said Gurudath Gurjal, MSc, Director of ClinTrek Research.

Why the Jeeva CRO Partnership Program?
Encouraged by the success of early partnerships in the U.S. and India, Jeeva is extending an invitation to CROs specializing in obesity, dermatology, oncology, and rare diseases to scale the adoption of its next-generation, AI-enabled CTMS platform. The standard CRO model has focused on integrating numerous point solutions and manual time & materials contracting with heavy-duty manual labor. Jeeva is leading a change driven by tech innovation and visionary leadership.

Partner CROs will gain access to:
1️⃣ A Unified or Modular, AI-Powered CTMS for Seamless Sponsor-CRO-Site Collaboration
🔹 Real-time data synchronization between all stakeholders
🔹 Automated workflows & AI-driven continuous learning and engagement for faster decision-making
🔹 Built-in compliance with 21 CFR Part 11, ICH-GCP, HIPAA, and GDPR
“The future of clinical trials will be defined by how well we can integrate data, processes, and regulatory compliance in one place. Jeeva’s platform is a game-changer for niche CROs like ours focused on clinical data management and biostatistics,” said Rajendra Prasad Ponugoti, CEO of VAICS Consulting.

2️⃣ Accelerated Study Timelines & Reduced Site Burden
🔹 eConsent, ePRO, and remote patient monitoring for decentralized & hybrid trials
🔹 Streamlined recruitment & patient engagement to minimize dropout rates
🔹 Automated regulatory submissions to reduce administrative workload
“Rare disease trials are already complex enough without the added burden of fragmented trial management. Jeeva’s AI-powered CTMS offers a way to streamline operations and ensure regulatory compliance, ultimately improving access to life-saving treatments,” said Robert Freishtat, MD, President of Uncommon Cures.

3️⃣ Cost-Effective Trial Execution & Scalable Growth
🔹 Reduce study costs with a pay-as-you-go model
🔹 Eliminate unnecessary site visits & operational inefficiencies
🔹 Scale seamlessly across multilingual global study sites
“By partnering with Jeeva, CROs can modernize their operations and gain a competitive edge in delivering efficient, AI-driven clinical trials,” added Harsha K Rajasimha, PhD, CEO of Jeeva. “Together, we can significantly reduce trial timelines and improve patient outcomes across key therapeutic areas.” Sunil Tadepalli, MD, CEO, Labnetworx is also an official distributor of Jeeva Solutions in India.

The Future of CRO-Sponsor Collaboration: Who Should Join?
Jeeva is actively seeking partnerships with niche forward-thinking CROs, Site networks, or Academic Research Organizations (AROs) that:
✔ Specialize in therapeutic areas such as obesity, dermatology, oncology, or rare disease trials
✔ Embrace AI, automation, and digital transformation
✔ Prioritize patient-centric trial execution
✔ Seek to scale their operations with a technology-first approach

Next Steps: How to Join the Jeeva CRO Partnership Program
CROs, academic medical centers considering launching an ARO, or Site management organizations interested in leveraging Jeeva’s AI-powered CTMS and being at the forefront of the next wave of clinical trial innovation can apply for partnership by visiting Jeeva CRO Partnership Program or reaching out to [email protected].
Selected partners will receive:
🔹 Access to Jeeva’s CTMS & AI capabilities for jointly offering combined solutions to sponsors
🔹 Personalized onboarding & technology integration support
🔹 Co-marketing opportunities with Jeeva to drive industry visibility

About Jeeva Clinical Trials
Jeeva is a leading provider of decentralized clinical trial (DCT) solutions, AI-powered patient engagement tools, and next-generation CTMS technology. Designed to increase profit margins for CROs through efficiency gains, Jeeva helps you accelerate patient recruitment, maximize retention, reduce site burden, and enhance compliance. Jeeva enables you to collaborate seamlessly in real time with sponsors and sites.
Jeeva’s technology is trusted by biopharma sponsors, CROs, academic medical centers, and patient advocacy groups worldwide to execute faster, more cost-effective, and scalable trials.
For more information, visit www.jeevatrials.com.

📢 Contact for Media & Partnerships
📍 Jeeva Clinical Trials, Manassas, VA
📧 [email protected]
🌐 Jeeva CRO Partnership Program

HARSHA K RAJASIMHA
Jeeva Clinical Trials Inc
+1 703-968-7023
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
Other

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.